CST3 and Parkinson disease: The major strengths of our study were the inclusion of subjects with comparable clinical parameters and the utilization of different biospecimen types that were derived from the same PD patients and controls, which facilitated an evaluation of the most appropriate biospecimen type for cystatin C quantification in PD.